Related Experiment Video
Updated: Apr 4, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide in angiodysplasia-related bleeding.
J P Boey1, U Hahn2, S Sagheer3
1Department of Haematology, Flinders Medical Centre, Adelaide, South Australia, Australia.
Thalidomide is a promising treatment for gastrointestinal bleeding caused by angiodysplastic lesions, offering the best available evidence despite potential side effects.
Area of Science:
- Gastroenterology
- Hematology
Background:
- Angiodysplastic lesions cause gastrointestinal bleeding that is hard to diagnose and treat with endoscopy.
- Patients frequently need significant blood transfusions.
Observation:
- Thalidomide shows promise for managing angiodysplasia-related bleeding.
- This study reviews existing literature and presents clinical experience.
Findings:
- Thalidomide is the most evidence-based treatment for refractory angiodysplastic lesion bleeding.
- Despite its side-effect profile, it is a valuable therapeutic option.
Implications:
- Thalidomide offers a viable medical strategy for a challenging clinical problem.
- Further research may optimize its use in managing angiodysplastic bleeding.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Venous Thrombosis III: Interprofessional Care
Teratogenicity
Antihypertensive Drugs: Thiazide-Class Diuretics
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

